Levonorgestrel-releasing Intrauterine System – The discontinuing story

References

• Halmesmaki K, Hurskainen R, Tiitinen A, Teperi J, Grenman S, Kivela A, Kujansuu E, Yliskoski M, Paavonen J. A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms. Hum Reprod 2004; 19: 378–382
   PubMed Web of Science ®Google Scholar
• British-National-Formulary. Intrauterine progestogen-only system. September 2007; 54: 430–431
   Google Scholar
• National-Institute-for-Health-and-Clinical-Excellence. Heavy Menstrual Bleeding. 2007, NICE Clinical Guidelines 44
   Google Scholar
• Nagrani R, Bowen-Simpkins P, Barrington J W. Can the levonorgestrel intrauterine system replace surgical treatment for the management of menorrhagia?. BJOG 2002; 109: 345–347
   PubMed Web of Science ®Google Scholar
• Lahteenmaki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J, Nilsson C G. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998; 316: 1122–1126
   PubMed Web of Science ®Google Scholar
• National-Institute-for-Health-and-Clinical-Excellence. Long-acting reversible contraception. NICE Clinical Guidelines 30. RCOG, London 2005
   Google Scholar
• Halmesmaki K, Hurskainen R, Teperi J, Grenman S, Kivela A, Kujansuu E, Tuppurainen M, Yliskoski M, Vuorma S, Paavonen J. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on sexual functioning among women with menorrhagia: a 5-year randomised controlled trial. BJOG 2007; 114: 563–568
   PubMed Web of Science ®Google Scholar
• Backman T, Huhtala S, Blom T, Luoto R, Rauramo I, Koskenvuo M. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG 2000; 107: 335–339
   PubMed Web of Science ®Google Scholar
• Lockhat F B, Emembolu J E, Konje J C. Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. Fertil Steril 2005; 83: 398–404
   PubMed Web of Science ®Google Scholar
• Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49: 56–72
   PubMed Web of Science ®Google Scholar
• Crosignani P G, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997; 90: 257–263
   PubMed Web of Science ®Google Scholar
• Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994; 61: 70–77
   PubMed Web of Science ®Google Scholar
• Daud S, Ewies A A. Levonorgestrel-releasing intrauterine system: why do some women dislike it?. Gynecol Endocrinol 2008; 24: 686–690
   PubMed Web of Science ®Google Scholar
• Cox M, Tripp J, Blacksell S. Clinical performance of levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5 year report. J Fam Plann Reprod Health Care 2002; 28: 73–77
   PubMed Web of Science ®Google Scholar
• Cho S, Nam A, Kim H, Chay D, Park K, Cho D J, Park Y, Lee B. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol 2008; 198: 373 e1–e7
   Web of Science ®Google Scholar
• Kingman C E, Kadir R A, Lee C A, Economides D L. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004; 111: 1425–1428
   PubMed Web of Science ®Google Scholar
• Bayer-plc. Electronic Medicines Compendium: LNG-IUS, Available from: http://emc.medicines.org.uk/medicine/1829/SPC/Mirena/[Accessed 6 March 2009]
   Google Scholar
• Nilsson C G, Lahteenmaki P L, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 1984; 41: 52–55
   PubMed Web of Science ®Google Scholar
• RxList-The-Internet-Drug-Index. LNG-IUS, Available from: http://www.rxlist.com/mirena-drug.htm[Accessed 6 March 2009]
   Google Scholar
• Raudaskoski T, Tapanainen J, Tomas E, Luotola H, Pekonen F, Ronni-Sivula H, Timonen H, Riphagen F, Laatikainen T. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002; 109: 136–144
   PubMed Web of Science ®Google Scholar
• Ilse J R, Greenberg H L, Bennett D D. Levonorgestrel-releasing intrauterine system and new-onset acne. Cutis 2008; 82: 158
   Google Scholar
• World-Health-Organization-(WHO). Medical Eligibility Criteria for Contraceptive Use. WHO, Geneva, Switzerland 2000
   Google Scholar
• Fotherby K. Levonorgestrel. Clinical pharmacokinetics. Clin Pharmacokinet 1995; 28: 203–215
   PubMed Web of Science ®Google Scholar
• Bayer-plc. Electronic Medicines Compendium: Norgeston, Available from: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?DocumentID=1834#PHARMACOKINETIC_PROPS. [Accessed 24 December 2007]
   Google Scholar
• Weiner E, Victor A, Johansson E D. Plasma levels of d-norgestrel after oral administration. Contraception 1976; 14: 563–570
   PubMed Web of Science ®Google Scholar
• Ratsula K, Toivonen J, Lahteenmaki P, Luukkainen T. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device. Contraception 1989; 39: 195–204
   PubMed Web of Science ®Google Scholar
• Suhonen S P, Allonen H O, Lahteenmaki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995; 172: 562–567
   PubMed Web of Science ®Google Scholar
• Nilsson C G, Johansson E D, Luukkainen T. A d-norgestrel-releasing IUD. Contraception 1976; 13: 503–514
   PubMed Web of Science ®Google Scholar
• Xiao B L, Zhou L Y, Zhang X L, Jia M C, Luukkainen T, Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990; 41: 353–362
   PubMed Web of Science ®Google Scholar
• RxList-The-Internet-Drug-Index. Alesse, Available from: http://www.rxlist.com/alesse-drug.htm. [Accessed 6 March 2009]
   Google Scholar
• Wahab M, Al-Azzawi F. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2005; 112: 1455–1456
   PubMed Web of Science ®Google Scholar
• Nilsson C G, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 1982; 17: 529–536
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Fotherby K, Burrows G D, Laby B, Wood C. Plasma levels of ethinyl oestradiol and norgestrel during hormone replacement therapy. Maturitas 1980; 2: 147–154
   PubMed Web of Science ®Google Scholar
• RxList-The-Internet-Drug-Index. Seasonale, Available from: http://www.rxlist.com/seasonale-drug.htm. [Accessed 6 March 2009]
   Google Scholar
• Custodia-Lora N, Novillo A, Callard I P. Effect of gonadal steroids on progesterone receptor, estrogen receptor, and vitellogenin expression in male turtles (Chrysemys picta). J Exp Zoolog A Comp Exp Biol 2004; 301: 15–25
   Google Scholar
• Okulicz W C. Temporal effects of progesterone inhibition of occupied nuclear oestrogen receptor retention in the rat uterus. J Endocrinol 1989; 121: 101–107
   PubMed Web of Science ®Google Scholar
• Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander E S, Golub T R. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 1999; 96: 2907–2912
   PubMed Web of Science ®Google Scholar
• Skrzypulec V, Drosdzol A. Evaluation of quality of life and sexual functioning of women using levonorgestrel-releasing intrauterine contraceptive system – LNG-IUS. Coll Antropol 2008; 32: 1059–1068
   PubMedGoogle Scholar
• Gorgen H, Api M, Akca A, Cetin A. Use of the levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users. 835–840, Arch Gynecol Obstet 2008;279
   Google Scholar
• Hurskainen R, Teperi J, Rissanen P, Aalto A M, Grenman S, Kivela A, Kujansuu E, Vuorma S, Yliskoski M, Paavonen J, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004; 291: 1456–1463
   PubMed Web of Science ®Google Scholar
• van Dongen H, van de Merwe A G, de Kroon C D, Jansen F W. The impact of alternative treatment for abnormal uterine bleeding on hysterectomy rates in a tertiary referral center. J Minim Invasive Gynecol 2009; 16: 47–51
   PubMed Web of Science ®Google Scholar
• Lockhat F B, Emembolu J O, Konje J C. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod 2005; 20: 789–793
   PubMed Web of Science ®Google Scholar